Allergan acquires NASH player Tobira for $1.695bn
In the first of two acquisitions announced on the same day, both focused on the emerging nonalcoholic steatohepatitis (NASH) market, Allergan PLC bought publicly traded Tobira Therapeutics Inc. for $1.695bn, including approximately $534mm up front plus up to $1.2bn in earn-outs.
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com